Showing 6881-6890 of 10618 results for "".
- Bimagrumab and Semaglutide in Obesity: Phase 2 Findingshttps://reachmd.com/news/bimagrumab-semaglutide-obesity-phase-2/2486955/Key Takeaways In obesity, bimagrumab-containing regimens, especially combination regimens, were associated with larger fat-mass and visceral-adiposity reductions and better lean-mass preservation than semaglutide alone. A high-dose combination was associated
- Randomized Trial of Oxygen-Enriched Epithelium-On CXL for Keratoconushttps://reachmd.com/news/randomized-trial-of-oxygen-enriched-epithelium-on-cxl-for-keratoconus/2486930/Key Takeaways At month 12, least squares mean Kmax improved by 0.5 D with treatment and worsened by 0.4 D with sham/placebo, with a significant between-group difference of -1.0 D. The phase 3, multicenter, sham procedure/placebo-controlled, double-mask
- Rapid Weight Loss Brings Expanding Soft Tissue Concerns to Dermatologyhttps://reachmd.com/news/rapid-weight-loss-brings-expanding-soft-tissue-concerns-to-dermatology/2486936/A new analysis suggests rapid weight loss from GLP-1 agents, bariatric surgery, or lifestyle change is associated with measurable declines in skin elasticity and soft tissue volume.Rapid and intentional weight loss (driven by bariatric surgery, glucagon-l
- Pembrolizumab Plus Chemotherapy in KEYNOTE-590 at 5 Yearshttps://reachmd.com/news/pembrolizumab-plus-chemotherapy-in-keynote-590-at-5-years/2486906/Key Takeaways Long-term overall survival remained higher with pembrolizumab plus chemotherapy during extended follow-up. Progression-free survival findings also favored the pembrolizumab-containing regimen over time. Grade 3 or higher treatmen
- 177Lu-PSMA-617 Outcomes in Octogenarians With mCRPChttps://reachmd.com/news/177lu-psma-617-outcomes-in-octogenarians-with-mcrpc/2486911/Key Takeaways More than half of patients had a PSA50 response, and progression-free and overall survival were reported in the same treated cohort. Hospitalization during therapy was common, and serious hematologic toxicities included anemia and thrombo
- ASCENT-04 Results for Frontline PD-L1+ TNBChttps://reachmd.com/news/ascent-04-results-frontline-pd-l1-tnbc/2486898/Key Takeaways Sacituzumab govitecan plus pembrolizumab was associated with longer progression-free survival than pembrolizumab plus chemotherapy in ASCENT-04/KEYNOTE-D19. Median progression-free survival was 11.2 months with the sacituzumab govitecan c
- Photobiomodulation Shows Vision Gains in Dry AMD at 24 Monthshttps://reachmd.com/news/photobiomodulation-vision-gains-dry-amd/2486895/Key Takeaways In LIGHTSITE III, most treated eyes gained at least 5 letters by month 21, and smaller proportions achieved gains of 10 or 15 letters. No phototoxicity was reported, ocular adverse-event rates were similar between groups, and progression
- Hepatic Arterial Infusion Oxaliplatin After Colorectal Liver Metastasis Resectionhttps://reachmd.com/news/hepatic-arterial-infusion-oxaliplatin-after-colorectal-liver-metastasis-resection/2486884/Key Takeaways Longer hepatic recurrence-free survival was observed with HAI oxaliplatin plus IV LV5FU2 than with IV oxaliplatin plus IV LV5FU2 after surgery for four or more colorectal liver metastases. Recurrence-free survival also favored HAI, while
- Dr. Lisa Swanson Presents on Communication, Therapeutics, and Confidence in Treating Children at Noahhttps://reachmd.com/news/dr-lisa-swanson-presents-on-communication-therapeutics-and-confidence-in-treating-children-at-noah/2486876/At the 67th Noah Worcester Dermatological Society Annual Meeting, Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, delivered the Alfred L. Weiner Lecture titled “Afraid to Treat Kids? Here are some Pearls to Help!” The session focused on practical, clinic-ready stra
- Symptom-Based Dosing In Neonatal Opioid Withdrawalhttps://reachmd.com/news/symptom-based-dosing-in-neonatal-opioid-withdrawal/2486860/Key Takeaways In ESC-managed infants, symptom-based dosing was associated with faster medical readiness for discharge than scheduled tapering. In the ESC cohort, treatment initiation and overall length of stay did not differ significantly, and the Finn